These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 4396459)

  • 21. Effects of amantadine and of some synthetic antiparkinsonian drugs on the behavioral response to L-DOPA in mice.
    Florio V; Longo VG
    Physiol Behav; 1971 Apr; 6(4):465-6. PubMed ID: 5148760
    [No Abstract]   [Full Text] [Related]  

  • 22. The pharmacotherapy of Parkinsonism.
    Pinder RM
    Prog Med Chem; 1972; 9(2):192-274. PubMed ID: 4147180
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of adrenolytic agents (alpha and beta blockaders), of a monoamine oxidase inhibitor and of an SH donor (Agr 307) on the serum glycuronidase increase induced by adrenaline infusion].
    Laborit H; Baron C; Laurent J
    Agressologie; 1974; 15(2):111-5. PubMed ID: 4447136
    [No Abstract]   [Full Text] [Related]  

  • 24. [Pathochemical bases for the treatment of parkinsonism].
    Petelin LS; Tret'iakova KA; Pigarev VA; Romenskaia LK
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1971 Dec; 71(12):1765-70. PubMed ID: 5143959
    [No Abstract]   [Full Text] [Related]  

  • 25. [l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics].
    Degkwitz R
    Med Klin; 1969 Aug; 64(33):1451-6. PubMed ID: 4896563
    [No Abstract]   [Full Text] [Related]  

  • 26. [Collateral effects of antiparkinsonian agents used in psychiatry].
    Daniel Falcón H
    Neurol Neurocir Psiquiatr; 1976; 17(1):47-55. PubMed ID: 29247
    [No Abstract]   [Full Text] [Related]  

  • 27. [Clinical aspects and drug therapy of Parkinson's syndrome].
    Mumenthaler M
    Schweiz Med Wochenschr; 1966 Apr; 96(15):479-84. PubMed ID: 4862148
    [No Abstract]   [Full Text] [Related]  

  • 28. [Regulation of the phagocyte activity of polymorphonuclear leukocytes by several medical agents].
    Metelitsa LA; Mogilevich SE; Luĭk AI
    Klin Lab Diagn; 1996; (4):26-8. PubMed ID: 8963554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of alkyl substitution in drugs. XXII. The antihistaminic and anticholinergic activity of a series of thio ether analogues of substituted diphenhydramines.
    Timmerman H; Rekker RF; Harms AF; Nauta WT
    Arzneimittelforschung; 1970 Sep; 20(9):1258-9. PubMed ID: 4395035
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of a number of drugs with different pharmacological properties upon reserpine induced hypothermia in mice.
    van Riezen H; Delver A
    Arzneimittelforschung; 1971 Oct; 21(10):1562-6. PubMed ID: 4400402
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effect of drugs on fall-out nystagmus and Bekhterev nystagmus].
    Epshteĭn EP
    Kosm Biol Med; 1972; 6(6):34-8. PubMed ID: 4148630
    [No Abstract]   [Full Text] [Related]  

  • 32. [Treatment of Parkinson's syndrome with L-dopa].
    Kaeser HE; Ferel D; Wurmser P
    Schweiz Med Wochenschr; 1970 May; 100(19):805-13. PubMed ID: 4924276
    [No Abstract]   [Full Text] [Related]  

  • 33. A comparison of antagonists of physostigmine-induced suppression of behavior.
    Vaillant GE
    J Pharmacol Exp Ther; 1967 Sep; 157(3):636-48. PubMed ID: 4963332
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparison of five clinically used inhibitors of monoamine oxidase using the fluorescence microscopy method.
    Bartonícek V
    Med Pharmacol Exp Int J Exp Med; 1967; 16(2):142-6. PubMed ID: 5298397
    [No Abstract]   [Full Text] [Related]  

  • 35. Biochemical aspects of experimentally induced parkinsonism.
    Goldstein M; Anagnoste B; Battista AF; Nakatani S; Ogawa M
    Res Publ Assoc Res Nerv Ment Dis; 1972; 50():434-47. PubMed ID: 4403657
    [No Abstract]   [Full Text] [Related]  

  • 36. [Features of medical therapy of Parkinson's syndrome].
    BIRKMAYER W; MENTASTI M
    Wien Klin Wochenschr; 1962 Oct; 74():700-2. PubMed ID: 13971141
    [No Abstract]   [Full Text] [Related]  

  • 37. Meta- and para-hydroxy-1-cyanophenethylamines.
    Pinder RM; Burger A; Ariëns EJ
    Arzneimittelforschung; 1970 Feb; 20(2):245-6. PubMed ID: 4392556
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of parkinsonian akinesia].
    Travenets IA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1966; 66(5):703-6. PubMed ID: 5998829
    [No Abstract]   [Full Text] [Related]  

  • 39. [On various pharmacological properties of 3-(diphenylmethoxy)-8-isopropylnotropane].
    Engelhardt A; Wick H
    Arzneimittelforschung; 1967 Jul; 17(7):876-8. PubMed ID: 4387832
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacological study of piroheptine, a new antiparkinson drug. II. Anticholinergic, antihistaminic, and psychopharmacological actions and toxicity.
    Hitomi M; Watanabe N; Kumadaki N; Kumada S
    Arzneimittelforschung; 1972 Jun; 22(6):961-6. PubMed ID: 4403219
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.